NICE looks askance at UCB's Cimzia

U.K. cost-effectiveness watchdog NICE says it's "minded not to recommended" the UCB drug Cimzia as a treatment option for rheumatoid arthritis, citing uncertainty embedded in economic models submitted by the company. Report